Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy

BJU International

Volumn 111, Issue 8, 2013, Pages 1208-1214

  Kaplan, Joshua R ^a   Kowalczyk, Keith J ^b   Borza, Tudor ^a   Gu, Xiangmei ^a   Lipsitz, Stuart R ^a   Nguyen, Paul L ^c   Friedlander, David F ^d   Trinh, Quoc Dien ^e   Hu, Jim C ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

outcomes; prostate cancer; radiation therapy; radical prostatectomy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84878338239     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12079     Document Type: Article

References (34)

1. Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61: 480-487
2. Abdollah F, Cozzarini C, Suardi N, et al. Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. Int J Radiat Oncol Biol Phys 2012; 83: 624-629
3. Spiess PE, Lee AK, Busby JE, et al. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 2007; 99: 321-325 (Pubitemid 46110434)
4. Bolla M, van Poppel H, Collette L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578
5. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930
6. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962
7. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479 (Pubitemid 43779173)
8. Johnstone PA, Assikis V, Goodman M, et al. Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes. Prostate Cancer Prostatic Dis 2007; 10: 185-188 (Pubitemid 46881670)
9. Da Pozzo LF, Cozzarini C, Briganti A, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009; 55: 1003-1011
10. Briganti A, Karnes RJ, Da Pozzo LF, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 2011; 59: 832-840
11. Murthy VH, Krumholz HM, Gross CP,. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-2726 (Pubitemid 38725421)
12. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732-748
13. Zippin C, Lum D, Hankey BF,. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76: 2343-2350
14. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs. open radical prostatectomy. JAMA 2009; 302: 1557-1564
15. Williams SB, Gu X, Lipsitz SR, et al. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer 2011; 117: 4846-4854
16. Rosenbaum PR, Donald RB,. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-524
17. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560 (Pubitemid 30660034)
18. Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL,. Androgen-deprivation therapy for non-metastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 2012; 61: 1119-1128
19. Nguyen PL, Je Y, Schutz FAB, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer. JAMA 2011; 306: 2359-2366
20. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527
21. Schmid HP, Mihatsch MJ, Hering F, et al. Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Eur Urol 1997; 31: 11-16 (Pubitemid 27058097)
22. Cheng L, Zincke H, Blute ML, et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 66-73 (Pubitemid 32052615)
23. Boorjian SA, Thompson RH, Siddiqui S, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178: 864-871 (Pubitemid 47211081)
24. Leibovici D, Spiess PE, Agarwal PK, et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007; 109: 198-204 (Pubitemid 46106234)
25. Showalter TN, Foley KA, Jutkowitz E, et al. Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis. Ann Oncol 2012; 23: 701-706
26. Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008; 26: 112-120
27. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-2335 (Pubitemid 44749360)
28. Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 2011; 60: 205-210
29. Kimura M, Mouraviev V, Tsivian M, et al. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 2010; 105: 191-201
30. Haukaas SA, Halvorsen OJ, Daehlin L, et al. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU Int 2006; 97: 51-55
31. Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002; 40: 49-54
32. Roach M, Desilvio M, Valicenti R, et al. Whole-pelvis, 'mini-pelvis,' or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006; 66: 647-653 (Pubitemid 44436716)
33. King CR, Kapp DS,. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 2008; 71: 346-350
34. King CR, Spiotto MT,. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008; 71: 23-27